Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Gastrointestinal stromal tumor (GIST)
Country:  U.S.A.
Trial Type:  Treatment
Results 1-15 of 15 for your search:
Start Over
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
Binimetinib and Imatinib Mesylate in Treating Patients with Untreated Advanced Gastrointestinal Stromal Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-162, NCI-2013-02281, NCT01991379
BGJ398 and Imatinib Mesylate in Treating Patients with Untreated Advanced Gastrointestinal Stromal Tumor
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-140, NCI-2014-02117, NCT02257541
A Study of PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors Including GIST
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PLX121-01, NCI-2015-00669, NCT02401815
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 21
Trial IDs: A6181196, NCI-2014-00205, 2011-002008-33, NCT01396148
Vandetanib in Treating Patients with Wild-Type Gastrointestinal Stromal Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 and over
Trial IDs: 13-C-0208, NCI-2014-02460, 130208, P131258, NCT02015065
Combined Vaccine Therapy in Treating Patients with Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-09138, NCI-2011-00920, NCT01376505
Sorafenib Tosylate and Capecitabine in Treating Patients With Advanced Breast or Gastrointestinal Tumors
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HIC # 1112009424, NCI-2013-00893, 1112009424, ONC-2010-35, NCT01640665
Dasatinib and Ipilimumab in Treating Patients with Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-083, NCI-2012-01165, CDR0000737378, 9172, NCT01643278
Ipilimumab and Imatinib Mesylate in Advanced Cancer
Phase: Phase I
Type: Treatment
Age: 15 and over
Trial IDs: 2012-0784, NCI-2013-00030, NCT01738139
Ganetespib and Ziv-Aflibercept in Treating Patients with Refractory or Metastatic Gastrointestinal Cancer, Non-small Cell Lung Cancer, Urothelial Cancer, or Sarcoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: 14-C-0150, NCI-2014-00626, 09-25-0099, 141525, P141525, 9605, NCT02192541
Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLOP628X2101, NCI-2015-00312, NCT02221505
Start Over